Entera Therapeutics

Entera Therapeutics is a clinical-stage biotechnology company focused on the oral delivery of peptide and protein therapeutics using its proprietary tablet-based delivery platform. The company is best known for developing oral formulations of parathyroid hormone candidates for hypoparathyroidism and osteoporosis, and it has expanded into obesity and metabolic disease through oral GLP-1 and related peptide programs. Entera has positioned its technology as a way to improve convenience and potentially expand the use of biologically active molecules that are traditionally administered by injection. Its pipeline includes wholly owned endocrine and metabolic programs as well as strategic collaborations aimed at oral peptide development. The company is publicly traded in the United States and operates with a relatively focused pipeline centered on endocrine and metabolic disorders.